A real-time evaluation of single CTCs complementary to bulk sample analysis (i.e., tumor biopsies and ctDNA) in a larger cohort of patients is needed to confirm the clinical relevance of CTCs in depicting critical genomic events that drive resistance to ALK-TKIs in ALK-positive NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.